$KANT
KINETA, INC./DE

2016 Q2 Form 10-Q Financial Statement

#000119312516681317 Filed on August 15, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2015 Q2 2015
Revenue $1.451M $1.070M $4.312M
YoY Change 35.61% -16.27%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.120M $1.710M $6.320M
YoY Change 82.46% 54.52%
% of Gross Profit
Research & Development $7.404M $5.976M $22.52M
YoY Change 23.9% 34.52%
% of Gross Profit
Depreciation & Amortization $70.00K $70.00K $272.0K
YoY Change 0.0% -36.3%
% of Gross Profit
Operating Expenses $10.52M $7.685M $28.85M
YoY Change 36.88% 38.46%
Operating Profit -$9.068M -$6.615M -$24.53M
YoY Change 37.08% 56.44%
Interest Expense $20.00K $209.0K $599.0K
YoY Change -90.43% 201.01%
% of Operating Profit
Other Income/Expense, Net -$5.000K $205.0K $93.00K
YoY Change -102.44% -14.68%
Pretax Income -$9.050M -$6.620M -$25.04M
YoY Change 36.71% 58.78%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$9.053M -$6.619M -$25.04M
YoY Change 36.77% 58.76%
Net Earnings / Revenue -623.91% -618.6% -580.71%
Basic Earnings Per Share -$0.47 $0.12 $0.12
Diluted Earnings Per Share -$0.47 -$0.46 -$0.46
COMMON SHARES
Basic Shares Outstanding 19.14M 553.5K
Diluted Shares Outstanding 19.14M shares 14.52M

Balance Sheet

Concept 2016 Q2 2015 Q2 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.60M $13.80M
YoY Change 56.82%
Cash & Equivalents $42.64M $13.80M
Short-Term Investments
Other Short-Term Assets $1.119M $200.0K
YoY Change -50.0%
Inventory
Prepaid Expenses
Receivables $140.0K $900.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $43.90M $14.90M
YoY Change 40.57%
LONG-TERM ASSETS
Property, Plant & Equipment $456.0K $600.0K
YoY Change 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $102.0K $3.200M
YoY Change 433.33%
Total Long-Term Assets $852.0K $3.800M
YoY Change 216.67%
TOTAL ASSETS
Total Short-Term Assets $43.90M $14.90M
Total Long-Term Assets $852.0K $3.800M
Total Assets $44.75M $18.70M
YoY Change 58.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.741M $3.300M
YoY Change 73.68%
Accrued Expenses $3.057M $2.200M
YoY Change 46.67%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.32M $9.800M
YoY Change 63.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $100.0K
YoY Change -99.03%
Other Long-Term Liabilities $2.800M $4.600M
YoY Change 24.32%
Total Long-Term Liabilities $2.800M $4.700M
YoY Change -66.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.32M $9.800M
Total Long-Term Liabilities $2.800M $4.700M
Total Liabilities $14.14M $14.50M
YoY Change -27.5%
SHAREHOLDERS EQUITY
Retained Earnings -$137.3M
YoY Change
Common Stock $20.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.61M $4.200M
YoY Change
Total Liabilities & Shareholders Equity $44.75M $18.70M
YoY Change 58.47%

Cashflow Statement

Concept 2016 Q2 2015 Q2 2015
OPERATING ACTIVITIES
Net Income -$9.053M -$6.619M -$25.04M
YoY Change 36.77% 58.76%
Depreciation, Depletion And Amortization $70.00K $70.00K $272.0K
YoY Change 0.0% -36.3%
Cash From Operating Activities -$6.810M -$2.060M -$19.42M
YoY Change 230.58% 124.25%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K $263.0K
YoY Change 0.0% 52.91%
Acquisitions
YoY Change
Other Investing Activities $10.00K $0.00
YoY Change
Cash From Investing Activities $0.00 -$10.00K -$260.0K
YoY Change -100.0% 52.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -350.0K -360.0K 24.73M
YoY Change -2.78% 64.54%
NET CHANGE
Cash From Operating Activities -6.810M -2.060M -19.42M
Cash From Investing Activities 0.000 -10.00K -260.0K
Cash From Financing Activities -350.0K -360.0K 24.73M
Net Change In Cash -7.160M -2.430M 5.050M
YoY Change 194.65% -18.55%
FREE CASH FLOW
Cash From Operating Activities -$6.810M -$2.060M -$19.42M
Capital Expenditures -$10.00K -$10.00K $263.0K
Free Cash Flow -$6.800M -$2.050M -$19.68M
YoY Change 231.71% 122.86%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Assets
Assets
18690000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
287000
CY2014Q4 us-gaap Cash
Cash
8793000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1607000
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
0
CY2015Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Cash
Cash
13844000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
571137 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
571137 shares
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
182000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14942000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13844000
CY2015Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
918000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4265000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3330000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4076000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
436000
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
12115000
CY2015Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46562000
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2248000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
180000
CY2015Q4 us-gaap Liabilities
Liabilities
14500000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18690000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9836000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
20000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
144000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
566000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-108102000
CY2015Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
149392
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
112292000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-120218000
CY2015Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
110057398 shares
CY2015Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
104854769 shares
CY2015Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
104854769 shares
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
294000
CY2015Q4 pti Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
185000
CY2015Q4 pti Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
2744000
CY2015Q4 pti Preferred Stock Warrant Liability
PreferredStockWarrantLiability
110000
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19183039 shares
CY2015Q2 us-gaap Cash
Cash
1872000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1223000
CY2016Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
91000
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Cash
Cash
42642000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19139486 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19139486 shares
CY2016Q2 us-gaap Assets
Assets
44753000
CY2016Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
191000
CY2016Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
191000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
43901000
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10479000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
57000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42642000
CY2016Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
140000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
20000
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2543000
CY2016Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3741000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4326000
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
612000
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
167855000
CY2016Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3057000
CY2016Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
543368 shares
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1119000
CY2016Q2 us-gaap Liabilities
Liabilities
14140000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44753000
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11315000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
124000
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
102000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
456000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
30613000
CY2016Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-137262000
CY2016Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2016Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2016Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2016Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
294000
CY2016Q2 pti Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1098000
CY2016Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
10.8102 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7964872 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6921000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
119000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3030000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-11.10
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
129000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-11.10
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
20000
us-gaap Revenues
Revenues
1877000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-317000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
479000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-67000
us-gaap Operating Expenses
OperatingExpenses
13509000
us-gaap Net Income Loss
NetIncomeLoss
-12359000
us-gaap Interest Expense
InterestExpense
410000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-19000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1159000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6033000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2379000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6033000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-101000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11632000
us-gaap Paid In Kind Interest
PaidInKindInterest
410000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-316000
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
10565000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2987000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
373000
us-gaap Share Based Compensation
ShareBasedCompensation
38000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4239000
pti Deferred Offering Costs Included In Accounts Payable And Accrued Expense
DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense
1153000
pti Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
299000
pti Noncash Rent Expense
NoncashRentExpense
23000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6586000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
28000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
112292000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
805000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
543368 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5416000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
pti Modifications Of Preferred Stock
ModificationsOfPreferredStock
-10565000
dei Entity Registrant Name
EntityRegistrantName
PROTEOSTASIS THERAPEUTICS, INC.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1766324 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001445283
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
805000
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28798000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
142000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
89000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-82000
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2Y6M
us-gaap Revenues
Revenues
2609000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1079000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
13000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
939000
us-gaap Operating Expenses
OperatingExpenses
19696000
us-gaap Net Income Loss
NetIncomeLoss
-17044000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-19000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-778000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
13000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-18422000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1491000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18422000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-42000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17087000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
44028000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
3971000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1472000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
6800000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Nature of the Business</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Proteostasis Therapeutics, Inc. (the &#x201C;Company&#x201D;) was incorporated in Delaware on December&#xA0;13, 2006. The Company is an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company&#x2019;s initial therapeutic focus is on cystic fibrosis, which is caused by defects in the cystic fibrosis transmembrane conductance regulator (&#x201C;CFTR&#x201D;) protein and insufficient CFTR protein function. The Company&#x2019;s lead product candidate, PTI-428, is in early clinical development, and the Company&#x2019;s other drug candidates are in the discovery phase.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and ability to secure additional capital to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The Company&#x2019;s financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities in the ordinary course of business. Through June&#xA0;30, 2016, the Company has primarily funded its operations with proceeds received from its initial public offering, proceeds from the sale of convertible preferred stock and, to a lesser extent, payments received in connection with collaboration agreements and research grants. The Company has incurred losses and negative cash flows from operations and had an accumulated deficit of $137,262 as of June&#xA0;30, 2016. The Company expects to continue to generate losses for the foreseeable future. As of June&#xA0;30, 2016, the Company expects that its cash of $42,642 will be sufficient to fund its operating expenses and capital expenditure requirements through at least the second quarter of 2017. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Reverse Stock Split</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> On January&#xA0;19, 2016, the Company effected a 1-for-10.8102 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company&#x2019;s Preferred Stock. Accordingly, all share and per share amounts for all periods presented in the accompanying financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Initial Public Offering</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In February 2016, the Company issued and sold 6,250,000 shares of its common stock in its initial public offering (&#x201C;IPO&#x201D;) at a public offering price of $8.00 per share, for net proceeds of $42,529 after deducting underwriting discounts and commissions of $3,500 and other offering expenses of $3,971. Upon the closing of the IPO, all shares of convertible preferred stock then outstanding converted into an aggregate of 9,699,600 shares of common stock, and the Company issued 2,590,742 shares of common stock as payment of $36,016 of accruing dividends due to holders of Series A preferred stock. In addition, the Company&#x2019;s convertible preferred stock warrant outstanding at the close of the IPO converted to a warrant to purchase common stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> In connection with the completion of the IPO, the Company amended its certificate of incorporation to authorize the future issuance of up to 5,000,000 shares of undesignated preferred stock, par value $0.001 per share. As of June&#xA0;30, 2016, there were no shares of preferred stock issued or outstanding.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Unaudited Interim Financial Information</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The accompanying unaudited interim financial statements as of June&#xA0;30, 2016 and for the three months and six months ended June&#xA0;30, 2016 and 2015 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;) have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These interim financial statements should be read in conjunction with the Company&#x2019;s&#xA0;audited financial statements and the notes thereto for the year ended December&#xA0;31, 2015 included in the Company&#x2019;s&#xA0;Annual Report on Form 10-K filed with the SEC on March&#xA0;30, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The unaudited interim financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited interim financial statements contain all adjustments which are necessary for a fair statement of the Company&#x2019;s financial position as of June&#xA0;30, 2016 and results of operations for the six months ended June&#xA0;30, 2016 and 2015 and cash flows for the six months ended June&#xA0;30, 2016 and 2015. Such adjustments are of a normal and recurring nature. The results of operations for the three and six months ended June&#xA0;30, 2016 are not necessarily indicative of the results of operations that may be expected for the year ending December&#xA0;31, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b><i>Revision of Previously Issued Financial Information</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; LINE-HEIGHT: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> As presented in Note 8 and within the accompanying statements of operations and comprehensive loss, the Company has revised basic net income per share attributable to common stockholders and diluted net loss per share attributable to common stockholders for the three months ended June 30, 2015 from the amounts presented in error in the unaudited quarterly financial data footnote in the previously filed Form 10-K for the year ended December 31, 2015. Amounts previously reported for basic and diluted net income per share did not appropriately present the allocation of income to participating securities and reflect the impact of certain potential common shares. These revisions decreased basic net income attributable to common stockholders from $3.24 per share to $0.12 per share and reduced diluted net income attributable to common stockholders from $3.24 per share to a loss of $0.46 per share. Based upon the Company&#x2019;s evaluation of relevant factors, the Company concluded that the revisions to the basic and diluted net income (loss) attributable to common stockholders within the consolidated statement of operations and comprehensive loss are not material to the previously issued quarterly financial data.</p> </div>
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15211000
us-gaap Interest Income Operating
InterestIncomeOperating
20000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual for research and development expenses and the valuation of common stock, preferred stock warrant liability and derivative liability. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.</p> </div>
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.826 pure
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0065 pure
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
62000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14953022 shares
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On January 19, 2016, the Company effected a 1-for-10.8102 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios for each series of the Company's Preferred Stock.
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
112292000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46500000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42529000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14953022 shares
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000
dei Trading Symbol
TradingSymbol
PTI
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14280000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2515000
us-gaap Share Based Compensation
ShareBasedCompensation
805000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
1378000
pti Stockholders Equity Reverse Stock Split Effective Date
StockholdersEquityReverseStockSplitEffectiveDate
2016-01-19
pti Change In Fair Value Of Derivative Liability
ChangeInFairValueOfDerivativeLiability
89000
pti Prepaid Rent Expense
PrepaidRentExpense
87000
pti Stock Issued For Payment Of Accrued Dividends
StockIssuedForPaymentOfAccruedDividends
3000
pti Stock Issued For Payment Of Accrued Bonus
StockIssuedForPaymentOfAccruedBonus
62000
pti Conversion Of Preferred Stock Warrants Into Common Stock Warrants
ConversionOfPreferredStockWarrantsIntoCommonStockWarrants
28000
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2015Q2 us-gaap Revenues
Revenues
1070000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
205000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
7685000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-6619000
CY2015Q2 us-gaap Interest Expense
InterestExpense
209000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9053000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9068000
CY2015 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1M13D
CY2015 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.741 pure
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Interest Income Operating
InterestIncomeOperating
20000
CY2016Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
2590742 shares
CY2016Q1 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
9699600 shares
CY2016Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
9699600 shares
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19139183 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19139183 shares
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7404000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1709000
CY2015 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0014 pure
CY2015 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
984160 shares
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-400000
CY2015Q2 pti Net Income Loss Available To Convertible Preferred Stockholders
NetIncomeLossAvailableToConvertiblePreferredStockholders
1726000
CY2015Q2 pti Net Income Loss Available To Convertible Preferred Stockholders Diluted
NetIncomeLossAvailableToConvertiblePreferredStockholdersDiluted
-1726000
CY2015Q2 pti Temporary Equity Accretion To Redemption Value Adjustment Diluted
TemporaryEquityAccretionToRedemptionValueAdjustmentDiluted
-2152000
CY2015Q2 pti Preferred Stock Conversions Adjustments Diluted
PreferredStockConversionsAdjustmentsDiluted
10565000
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1766324 shares
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
497000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3115000
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2016Q2 us-gaap Revenues
Revenues
1451000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
10519000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-9053000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9053000
CY2015Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
13962472 shares
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6619000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
68000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6615000
CY2015Q2 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
10565000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14515998 shares
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
553526 shares
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5976000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
478000
CY2015Q2 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2152000

Files In Submission

Name View Source Status
0001193125-16-681317-index-headers.html Edgar Link pending
0001193125-16-681317-index.html Edgar Link pending
0001193125-16-681317.txt Edgar Link pending
0001193125-16-681317-xbrl.zip Edgar Link pending
d220778d10q.htm Edgar Link pending
d220778dex109.htm Edgar Link pending
d220778dex311.htm Edgar Link pending
d220778dex312.htm Edgar Link pending
d220778dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pti-20160630.xml Edgar Link completed
pti-20160630.xsd Edgar Link pending
pti-20160630_cal.xml Edgar Link unprocessable
pti-20160630_def.xml Edgar Link unprocessable
pti-20160630_lab.xml Edgar Link unprocessable
pti-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending